Biomarkers

iOnctura Project Evaluating Novel PI3Kδ-inhibitor IOA-244 in Lymphoma to be Co-funded by Innosuisse

Retrieved on: 
Tuesday, July 27, 2021
Branches of biology, Biology, Biomarkers, Cell biology

The research project, scheduled to start in August 2021, will run alongside iOncturas expanding clinical program for IOA-244, focussed on the treatment of solid tumors (NCT04328844).

Key Points: 
  • The research project, scheduled to start in August 2021, will run alongside iOncturas expanding clinical program for IOA-244, focussed on the treatment of solid tumors (NCT04328844).
  • Amongst other aspects, the new project will explore patient stratification biomarkers, combination interventions to increase treatment response rates in lymphoma and methods for minimizing potential resistance pathways.
  • I am delighted iOnctura will be able to draw on the experience of Francesco Bertoni and his group to better understand the mechanisms of resistance in lymphoma.
  • Project funding comes from Innosuisse, the Swiss national Innovation Agency which has a remit to promote science-based innovation to increase the competitiveness of small and medium-sized enterprises in Switzerland.

INmune Bio, Inc. Announces Design of Upcoming Phase 2 Alzheimer’s Disease Clinical Trial and New Phase 1b AD Biomarker Data

Retrieved on: 
Monday, July 26, 2021
Branches of biology, Biology, Neuroscience, Biomarkers, Psychiatric diagnosis, Neurology, Myelin, Axon, Alzheimer's disease, Neuroinflammation, Wallerian degeneration

Boca Raton, FL, July 26, 2021 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced the design of its upcoming Phase 2 clinical trial of XProTM in patients diagnosed with mild Alzheimer’s disease (AD). The announcement is accompanied by the release of additional biomarker data from the Phase 1b AD trial that shows improvement in white matter (myelinated axons) that degenerate in AD patients.  

Key Points: 
  • The announcement is accompanied by the release of additional biomarker data from the Phase 1b AD trial that shows improvement in white matter (myelinated axons) that degenerate in AD patients.
  • "This is the first time in my career that I have seen positive changes, and in such a short time frame.
  • "Apparent fiber density decreases with axonal degeneration, and this is always seen in Alzheimer's disease patients.
  • In the Phase 1b study, we demonstrated XProTM significantly decreased biomarkers of neuroinflammation in Alzheimers patients.

Latin America In-Vitro Diagnostic Tests Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 26, 2021
Biotechnology, Health, Medical devices, Airlines, Branches of biology, Holding companies, Biomarkers, Tumor marker, Prenatal testing, Medical test, LATAM Airlines Group, IVD

The "The Market for In Vitro Diagnostic Tests in Latin America" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Market for In Vitro Diagnostic Tests in Latin America" report has been added to ResearchAndMarkets.com's offering.
  • Latin America (LATAM) is a key target for IVD manufacturers exploring expansion opportunities.
  • This report, The Market for In Vitro Diagnostic Tests in Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela and other nations), focuses on the market for reagents and instruments in the most important countries of the continent.
  • Immunoassay (non-microbiology): hormones, tumor markers, bone markers, oncology markers, autoimmunity, allergy, anemia, neonatal tests, prenatal tests, interleukins, PCT.

MindX Sciences issued a second patent on risk assessment of suicidality

Retrieved on: 
Monday, July 26, 2021
Branches of biology, Biology, Biomarkers, Life sciences

INDIANAPOLIS, July 26, 2021 /PRNewswire/ --MindX Sciences Inc. announced that it has been awarded a second US patent for risk assessment of suicidality, licensed from Indiana University.

Key Points: 
  • INDIANAPOLIS, July 26, 2021 /PRNewswire/ --MindX Sciences Inc. announced that it has been awarded a second US patent for risk assessment of suicidality, licensed from Indiana University.
  • The patent covers "biomarkers and methods of screening expression levels of the biomarkers for predicting and tracking suicidality, as well as for monitoring response to a treatment for suicidal risk and for determining suicidal risk as a side effect of anti-depressants."
  • Niculescu, MD, PhD, Chairman and Founder of MindX Sciences stated "the granting of a second patent on objective biomarkers is a great step forward in assessing and preventing suicide risk at a biological level.
  • MindX Sciences Inc. works to improve lives through empowering precision medicine approaches to mental health.

MindX Sciences issued a second patent on risk assessment of suicidality

Retrieved on: 
Monday, July 26, 2021
Articles, Academic disciplines, Biomarkers, Suicide, Risk, Patent

INDIANAPOLIS, July 26, 2021 /PRNewswire/ --MindX Sciences Inc. announced that it has been awarded a second US patent for risk assessment of suicidality, licensed from Indiana University.

Key Points: 
  • INDIANAPOLIS, July 26, 2021 /PRNewswire/ --MindX Sciences Inc. announced that it has been awarded a second US patent for risk assessment of suicidality, licensed from Indiana University.
  • MindX Sciences has been granted the second patent for the risk assessment of suicide... a patient dies every 40 seconds.
  • Niculescu, MD, PhD, Chairman and Founder of MindX Sciences stated "the granting of a second patent on objective biomarkers is a great step forward in assessing and preventing suicide risk at a biological level.
  • MindX Sciences Inc. works to improve lives through empowering precision medicine approaches to mental health.

Catalyst Biosciences Announces First Patient Screened for CFI deficiency in its CB 4332 Screening and Natural History of Disease Studies

Retrieved on: 
Thursday, July 22, 2021
Branches of biology, Medicine, Clinical medicine, Biomarkers, Cell biology, Screening

"The findings from the CFI deficiency screening and natural history of disease studies will be instrumental in identifying patients for the Phase 1/2 trial of CB 4332, planned for mid-year 2022, said Nassim Usman, Ph.D., president and chief executive officer of Catalyst.

Key Points: 
  • "The findings from the CFI deficiency screening and natural history of disease studies will be instrumental in identifying patients for the Phase 1/2 trial of CB 4332, planned for mid-year 2022, said Nassim Usman, Ph.D., president and chief executive officer of Catalyst.
  • Following the disease manifestations and biomarkers of this complement disorder will be important in unlocking the full therapeutic potential of CB 4332.
  • The ConFIrm screening study will measure CFI levels and activity in patients who have diseases related to a CFI deficiency and who may potentially benefit from CB 4332 treatment.
  • The findings from these studies will identify opportunities to potentially develop CB 4332 for treatment in multiple indications.

Congenica Receives CE Mark for Genomic Analysis Software

Retrieved on: 
Wednesday, July 21, 2021
Branches of biology, Biology, Life sciences, Biotechnology, Emerging technologies, Biomarkers, Chemical pathology, Personalized medicine, Medical device, In vitro, Molecular diagnostics

Cambridge, United Kingdom 21 July 2021 - Congenica , the digital health company enabling rapid and accurate analysis of complex genomic data to transform peoples lives, today announces that its genomic interpretation software is now CE marked under the In Vitro Diagnostics Directive (98/79/EC).

Key Points: 
  • Cambridge, United Kingdom 21 July 2021 - Congenica , the digital health company enabling rapid and accurate analysis of complex genomic data to transform peoples lives, today announces that its genomic interpretation software is now CE marked under the In Vitro Diagnostics Directive (98/79/EC).
  • Medical devices require the CE mark designation for use in clinical applications in several key territories including the UK and the EU.
  • Congenicas world-leading genomic analysis technology platform supports the delivery of personalised medicine at scale, enabling rapid and accurate diagnoses for patients.
  • Congenicas world-leading software enables rapid genomic data analysis at scale and is the only product of its kind that has received the CE Mark under the In Vitro Diagnostics Directive.

Biospectal Raises $4.3M Seed Funding Led by Digital Health Investor, SeedLink

Retrieved on: 
Wednesday, July 21, 2021
Branches of biology, Biology, Health informatics, Articles, Biomarkers, Behavior modification, Digital therapeutics, Yamaha DTX series, Digital health, IOS, DTX

Remote patient monitoring and biosensing company will use investment to scale its OptiBP™ blood pressure measurement and monitoring product and operations worldwide; Renowned interventional cardiologist and inventor, Dr. Fred St. Goar, MD and SeedLink's Tim Juergens appointed to Biospectal's Board of Directors

Key Points: 
  • Biospectal will leverage the new funds to scale its OptiBPsmartphone blood pressure monitoring application and data platform technology worldwide.
  • Biospectal OptiBP for iOS is currently in alpha and is planned for public beta launch in the second half of 2021.
  • OptiBP's data also connects seamlessly with clinicians to support treatment regimens that help improve health and quality of life.
  • SeedLink SL supports founders in successfully establishing and growing solutions in the Digital Health space, with special focus on Digital Therapeutics (DtX), Digital Biomarkers, and platform-based business models.

Biospectal Raises $4.3M Seed Funding Led by Digital Health Investor, SeedLink

Retrieved on: 
Wednesday, July 21, 2021
Branches of biology, Biology, Health informatics, Articles, Biomarkers, Behavior modification, Digital therapeutics, Yamaha DTX series, Digital health, IOS, DTX

LAUSANNE, Switzerland and SAN FRANCISCO, July 21, 2021 /PRNewswire/ -- Biospectal SA, the remote patient monitoring and biosensing software company, today announced the closing of a $4.3M (€3.7M Euros) round of seed funding led by digital health investor, SeedLink, with additional funding from LabCorp, Athensmed, Swiss based Privilege Ventures and other European and US investors. Biospectal will leverage the new funds to scale its OptiBP™ smartphone blood pressure monitoring application and data platform technology worldwide. Biospectal OptiBP for Android launched in public beta in January 2021. Biospectal OptiBP for iOS is currently in alpha and is planned for public beta launch in the second half of 2021. View a short video of how Biospectal OptiBP works here.

Key Points: 
  • Biospectal will leverage the new funds to scale its OptiBPsmartphone blood pressure monitoring application and data platform technology worldwide.
  • Biospectal OptiBP for iOS is currently in alpha and is planned for public beta launch in the second half of 2021.
  • OptiBP's data also connects seamlessly with clinicians to support treatment regimens that help improve health and quality of life.
  • SeedLink SL supports founders in successfully establishing and growing solutions in the Digital Health space, with special focus on Digital Therapeutics (DtX), Digital Biomarkers, and platform-based business models.

Congenica Receives CE Mark for Genomic Analysis Software

Retrieved on: 
Wednesday, July 21, 2021
Branches of biology, Biology, Life sciences, Biotechnology, Emerging technologies, Biomarkers, Chemical pathology, Personalized medicine, Medical device, In vitro, Molecular diagnostics

Congenica Receives CE Mark for Genomic Analysis Software

Key Points: 
  • Cambridge, United Kingdom 21 July 2021 - Congenica , the digital health company enabling rapid and accurate analysis of complex genomic data to transform peoples lives, today announces that its genomic interpretation software is now CE marked under the In Vitro Diagnostics Directive (98/79/EC).
  • Medical devices require the CE mark designation for use in clinical applications in several key territories including the UK and the EU.
  • Congenicas world-leading genomic analysis technology platform supports the delivery of personalised medicine at scale, enabling rapid and accurate diagnoses for patients.
  • Congenicas world-leading software enables rapid genomic data analysis at scale and is the only product of its kind that has received the CE Mark under the In Vitro Diagnostics Directive.